Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial

– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful […]